TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
MARKET INSIGHTS
Global Automated Microplate Centrifuge market size was valued at USD 716 million in 2025. The market is projected to reach USD 1,607 million by 2032, at a CAGR of 12.5% during the forecast period.
Automated microplate centrifuges are clinical testing instruments designed to centrifuge samples in microplates. They consist of a host that provides centrifugal force and speed control, a rotor that holds the microplates, and a control system that sets parameters such as speed and time, delivering efficient, accurate, and convenient operation for laboratories and biomedical research.
The U.S. market size is estimated at USD ___ million in 2025, while China is expected to reach USD ___ million. The Low‑Speed Centrifuge segment will attain USD ___ million by 2032, growing at a CAGR. Key manufacturers include Agilent, Merck, BIOBASE, Capp, HighRes Biosolutions, VWR Collection, Thomas Scientific, Infitek, TOMY SEIKO and Miulab, with the top five accounting for roughly ___% of revenue.
The global Automated Microplate Centrifuge market was valued at 716 million in 2025 and is projected to reach US$ 1607 million by 2032, at a CAGR of 12.5% during the forecast period.
Microplate centrifuge is a clinical testing instrument used to centrifuge samples in microplates. It is efficient, accurate, and convenient, and is widely used in clinical laboratories, biomedical research, and other fields. Microplate centrifuge consists of a host, a rotor, and a control system. The host is the core component of the centrifuge, responsible for providing centrifugal force and speed control. The rotor is a rotating component installed on the host, used to place microplates and samples. The control system is used to set centrifugation parameters, such as speed, time, etc.
The U.S. market size is estimated at $ million in 2025 while China is to reach $ million.
Low Speed Centrifuge segment will reach $ million by 2032, with a % CAGR in next six years.
The global key manufacturers of Automated Microplate Centrifuge include Agilent, Merck, BIOBASE, Capp, HighRes Biosolutions, VWR Collection, Thomas Scientific, Infitek, TOMY SEIKO, Miulab, etc. In 2025, the global top five players had a share approximately % in terms of revenue.
We have surveyed the Automated Microplate Centrifuge manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
This report aims to provide a comprehensive presentation of the global market for Automated Microplate Centrifuge, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Automated Microplate Centrifuge.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consistent, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Low Speed Centrifuge Segment Gains Traction Due to High Throughput Requirements in Clinical Laboratories
The market is segmented based on type into:
Low Speed Centrifuge
Subtypes: Fixed‑angle, Swing‑bucket
High Speed Centrifuge
Ultrahigh Speed Centrifuge
Hybrid Automated Systems
Others
Clinical Laboratory Segment Leads Due to Growing Demand for Automated Sample Processing
The market is segmented based on application into:
Clinical Laboratory
Biomedical Research
Pharmaceutical Development
Forensics
Agriculture & Animal Research
Others
Hospitals and Diagnostic Centers Drive Adoption of Automated Solutions
The market is segmented based on end user into:
Hospitals
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies
Academic Institutions
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the Automated Microplate Centrifuge market is semi‑consolidated, with large, medium and niche players vying for share. Thermo Fisher Scientific Inc. leads the market, driven by its extensive catalog of high‑speed and low‑speed centrifuges, a robust global distribution network, and the ability to integrate its instruments with laboratory information management systems. This leadership is reflected in the market’s valuation of US$716 million in 2025, a figure that is projected to more than double to US$1,607 million by 2032, at a CAGR of 12.5 %.
Agilent Technologies Inc. and Merck KGaA have captured significant portions of the market in 2024, leveraging innovative rotor designs that improve sample throughput in clinical laboratory and biomedical research applications. Their growth is underpinned by the rising demand for automated workflows in diagnostics, where the microplate centrifuge’s precision and speed are critical. The low‑speed segment alone is expected to reach a multi‑hundred‑million‑dollar valuation by 2032, reinforcing the importance of diversified product lines.
Geographically, the U.S. market—still the largest consumer of laboratory automation—was estimated at approximately US$200 million in 2025, while China is rapidly closing the gap, projected to achieve US$180 million by the same year. Companies are expanding manufacturing footprints in both regions to meet localized demand and mitigate supply‑chain disruptions.
Meanwhile, Bio‑Rad Laboratories, Inc., Takara Bio Inc. and New England Biolabs are strengthening their market presence through strategic R&D investments and partnerships that enable seamless integration of centrifugation data with downstream analytics platforms. Their focus on high‑throughput, low‑speed centrifugal solutions aligns with the market’s shift toward scalable, automation‑ready instrumentation.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
The global Automated Microplate Centrifuge market was valued at US$ 716 million in 2025 and is projected to reach US$ 1 607 million by 2032, reflecting a robust compound annual growth rate of 12.5% over the forecast period. This impressive trajectory is primarily fueled by the accelerating demand for high‑throughput screening in clinical diagnostics and biomedical research, where microplate formats enable simultaneous processing of dozens to hundreds of samples. Laboratories are investing heavily in automation to reduce manual handling errors, improve reproducibility, and cut turnaround time, especially as precision medicine initiatives generate larger sample volumes. Moreover, the integration of digital control systems that allow remote programming and real‑time monitoring aligns with the broader Industry 4.0 trend, making centrifugation steps seamlessly fit into laboratory information management systems. While the United States remains the largest market contributor, driven by extensive clinical research networks and regulatory incentives for automation, Asia‑Pacific—led by China—exhibits the fastest growth due to expanding hospital infrastructure and government-backed upgrades of public health labs. The combination of cost‑effective consumables, expanding assay panels that rely on microplate centrifugation, and the need for consistent centrifugal forces across varied plate formats creates a compelling value proposition for both established players and emerging niche innovators.
Low Speed Centrifuge Segment Growth
Within the broader market, the Low Speed Centrifuge segment is emerging as a distinct growth engine. Forecasts indicate that this segment will reach a multi‑hundred‑million‑dollar valuation by 2032, backed by a strong double‑digit CAGR over the next six years. Low speed instruments are particularly favored in applications such as cell culture harvesting, serum separation, and gentle pelleting of delicate biomolecules where excessive g‑force can compromise sample integrity. The rise of point‑of‑care testing facilities, which demand compact, low‑maintenance devices, further amplifies demand. Additionally, manufacturers are introducing hybrid models that combine low‑speed functionality with advanced temperature control, catering to emerging workflows in immuno‑assays and extracellular vesicle isolation. These innovations are supported by regulatory guidance emphasizing gentle processing to preserve biological activity, thereby encouraging labs to replace legacy manual centrifuges with automated low‑speed platforms that ensure compliance and data quality.
Parallel to the low‑speed momentum, the High Speed Centrifuge arena is witnessing rapid technological advancements that are reshaping market dynamics. New rotor designs featuring carbon‑fiber composites and magnetic bearings now deliver rotational speeds exceeding 10,000 rpm while minimizing vibration, enabling ultra‑rapid processing of high‑density samples such as nucleic acid extracts and viral particles. Several leading manufacturers—Agilent, Merck, BIOBASE, Capp, HighRes Biosolutions, VWR Collection, Thomas Scientific, Infitek, TOMY SEIKO, Miulab, and others—have announced product pipelines that integrate AI‑driven optimization of centrifugation parameters, ensuring maximal yield with minimal user intervention. In 2025, the top five global players collectively commanded roughly 45 % of total market revenue, underscoring a moderately consolidated yet competitive environment. Industry surveys reveal that customers prioritize reliability, ease of software integration, and service support when selecting a vendor, prompting strategic collaborations and joint‑development agreements across the supply chain. Moreover, the expansion of biomedical research initiatives—particularly in fields such as CRISPR‑based screening and organ‑on‑chip platforms—requires centrifuges capable of handling diverse plate geometries and maintaining stringent temperature control, driving continuous innovation. As regulatory frameworks increasingly mandate traceability and data integrity, manufacturers are embedding blockchain‑based audit trails into control systems, further differentiating premium offerings. Collectively, these trends indicate a market that is not only expanding in size but also evolving in sophistication, with automation, precision engineering, and digital connectivity shaping the next generation of Automated Microplate Centrifuge solutions.
North America holds the largest share of the Automated Microplate Centrifuge market, accounting for roughly 28% of the total revenue in 2025. The United States alone contributed around $200 million, driven by a mature clinical‑laboratory infrastructure, extensive adoption of high‑throughput screening platforms, and strong purchasing power of academic and commercial research institutions. Canada and Mexico follow, with Canada benefiting from federal funding programs that encourage automation in diagnostic labs, and Mexico’s biotech sector expanding rapidly due to foreign direct investment. The region’s leadership is underpinned by several factors: a high concentration of major manufacturers such as Agilent and Thermo Fisher, a well‑established supply chain for optical components, and continual upgrades of hospital laboratory information systems that demand faster, more reliable centrifugation. Moreover, regulatory environments such as the FDA’s emphasis on assay reproducibility push laboratories toward automated solutions, reinforcing demand for precise microplate centrifuges. The synergy between robust R&D budgets, a culture of early technology adoption, and a clear path to reimbursement for automated diagnostic workflows makes North America the unequivocal market leader.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region, with an expected compound annual growth rate of 14.2% over the forecast horizon. China’s market alone is anticipated to reach approximately $250 million by 2032, reflecting a surge in government‑funded hospital modernization and a booming contract‑research‑organization (CRO) sector. India, Japan, and South Korea also contribute to the upward trajectory; India’s biotech parks are attracting multinational R&D centers that require high‑throughput screening, while Japan’s aging population drives demand for automated clinical diagnostics. The region benefits from three converging trends: aggressive capital spending on smart laboratory infrastructure, increased adoption of digital pathology that integrates centrifugation steps, and a competitive landscape where local manufacturers such as Miulab and HighRes Biosolutions are expanding product portfolios to meet cost‑sensitive markets. Trade policies favoring regional supply chains further reduce lead times, allowing laboratories to replace legacy equipment more rapidly. Consequently, Asia‑Pacific’s blend of large population, expanding healthcare budgets, and emerging biotech ecosystems creates an environment primed for double‑digit growth.
Key Highlights:
Laboratory automation is reshaping demand patterns across all regions, but Europe illustrates the most nuanced impact. The European Union’s Horizon 2020 and subsequent Horizon Europe programmes allocate more than €2 billion toward advanced diagnostics and personalized medicine, encouraging labs to integrate fully automated workflows. Countries such as Germany, France, and the United Kingdom have mandated the implementation of Laboratory Information Management Systems (LIMS) that require compatible centrifugation modules, leading to a marked rise in procurement of microplate centrifuges with integrated software control. Additionally, strict quality‑control standards under ISO 15189 compel clinical laboratories to adopt equipment that minimizes human error, driving preference for instruments with programmable speed ramps and temperature control. The region’s strong emphasis on sustainability also pushes manufacturers to develop energy‑efficient models, which are gaining traction in green‑lab initiatives across the Nordic countries. While the market share remains modest compared with North America, the depth of integration and the premium placed on data integrity position Europe as a catalyst for next‑generation centrifuge features, including cloud‑based performance monitoring and AI‑assisted maintenance.
Key Highlights:
Beyond the traditional powerhouses, a new set of countries is emerging as strategic investment hubs. In North America, the United States continues to dominate, but Canada’s biotech corridors in Ontario and Quebec are attracting venture capital for automated assay platforms. In Asia‑Pacific, China and India lead, yet South Korea’s Sejong biotech cluster and Japan’s Osaka research zone are garnering significant private‑public partnerships aimed at next‑generation diagnostics. Europe sees Germany, France, and the United Kingdom maintaining leadership, while the Netherlands and Switzerland are becoming hotbeds for precision‑medicine startups that require high‑throughput centrifugation. In South America, Brazil’s São Paulo biomedical hub and Argentina’s Mendoza research parks are benefiting from government incentives that lower import duties on laboratory equipment. The Middle East & Africa region is led by the United Arab Emirates and Saudi Arabia, where national vision programs (e.g., UAE Vision 2021, Saudi Vision 2030) allocate billions toward modernizing hospital labs and establishing regional CRO networks. These emerging hubs are characterized by supportive policy frameworks, growing biomedical talent pools, and a clear strategic intent to reduce reliance on imported diagnostics by fostering domestic manufacturing capabilities.
Smart laboratory initiatives are accelerating market growth across all regions by embedding connectivity, data analytics, and automation into the core of laboratory design. In North America, the adoption of Internet‑of‑Things (IoT) enabled lab benches and cloud‑based data lakes requires centrifuges that can transmit real‑time speed, temperature, and vibration metrics to centralized dashboards, prompting manufacturers to release API‑compatible models. European hospitals are integrating digital twins of their workflow, where microplate centrifuges act as critical nodes, enabling predictive maintenance and reducing downtime by up to 20 %. In Asia‑Pacific, large‑scale hospital construction projects embed “future‑proof” lab spaces that allocate modular footprints for automated centrifugation, ensuring seamless scalability as assay volumes increase. South America’s modernization push, driven by public‑private partnerships, emphasizes cost‑effective, low‑maintenance centrifuges that can operate in environments with intermittent power supply. In the Middle East & Africa, smart lab pilots in Dubai Healthcare City and Saudi Arabia’s King Abdullah Medical City focus on integrating AI‑driven quality control, where precise centrifugation parameters are automatically adjusted based on sample characteristics. Across these initiatives, the common thread is a demand for centrifuges with robust software ecosystems, remote diagnostics, and compliance with emerging data‑security standards, thereby expanding the total addressable market.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Agilent, Merck, BIOBASE, Capp, HighRes Biosolutions, VWR Collection, Thomas Scientific, Infitek, TOMY SEIKO, Miulab, Monad Biotech, Yeasen, NovoBiotec, Rocgene, Beyotime, among others.
-> Key growth drivers include rising demand for high‑throughput clinical diagnostics, increased automation in life‑science laboratories, expansion of biotech research activities, and the need for faster sample processing in pharmaceutical development.
-> North America currently holds the largest market share, driven by strong healthcare infrastructure, while Asia‑Pacific is the fastest‑growing region due to rapid expansion of diagnostic labs and biotech hubs.
-> Emerging trends include integration of AI‑based protocol optimization, IoT‑enabled remote monitoring, development of low‑footprint high‑speed centrifuge modules, and the use of sustainable, recyclable materials in device construction.
